Drug repurposing in oncology

Affiliations

¹ Department of Biomarker Research, Mosaiques Diagnostics, Hannover 30659, Germany. Electronic address: frantzi@mosaiques-diagnostics.com.
² Department of Biomarker Research, Mosaiques Diagnostics, Hannover 30659, Germany.
³ Department of Biomarker Research, Mosaiques Diagnostics, Hannover 30659, Germany; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
⁴ Biomedical Research Foundation of the Academy of Athens, Centre of Systems Biology, Athens, Greece.

Comment

Maria Frantzi et al. Lancet Oncol. 2020 Dec.

. 2020 Dec;21(12):e543.

doi: 10.1016/S1470-2045(20)30610-0.

¹ Department of Biomarker Research, Mosaiques Diagnostics, Hannover 30659, Germany. Electronic address: frantzi@mosaiques-diagnostics.com.
² Department of Biomarker Research, Mosaiques Diagnostics, Hannover 30659, Germany.
³ Department of Biomarker Research, Mosaiques Diagnostics, Hannover 30659, Germany; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
⁴ Biomedical Research Foundation of the Academy of Athens, Centre of Systems Biology, Athens, Greece.

No abstract available

Comment in

Drug repurposing in oncology - Authors' reply.
Tran AA, Prasad V. Tran AA, et al. Lancet Oncol. 2020 Dec;21(12):e544. doi: 10.1016/S1470-2045(20)30692-6. Lancet Oncol. 2020. PMID: 33271101 No abstract available.

Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy.
Tran AA, Prasad V. Tran AA, et al. Lancet Oncol. 2020 Sep;21(9):1134-1136. doi: 10.1016/S1470-2045(20)30424-1. Lancet Oncol. 2020. PMID: 32888447 No abstract available.